Prevalence of antibodies to SARS-CoV-2 in healthy blood donors in New York
Kamath, K.; Baum-Jones, E.; Jordan, G.; Haynes, W.; Waitz, R.; Shon, J.; Kujawa, S.; Fitzgibbons, L.; Kessler, D.; Luchsinger, L. L.; Yale IMPACT Team, ; Daugherty, P.
Show abstract
Despite the high level of morbidity and mortality worldwide, there is increasing evidence for asymptomatic carriers of the novel coronavirus SARS-CoV-2. We analyzed blood specimens from 1,559 healthy blood donors, collected in the greater New York metropolitan area between the months of March and July 2020 for antibodies to SARS-CoV-2 virus. Using our proprietary technology, SERA (Serum Epitope Repertoire Analysis), we observed a significant increase in SARS-CoV-2 seropositivity rates over the four-month period, from 0% [95% CI: 0 - 1.5%] (March) to 11.6% [6.0 - 21.2%] (July). Follow-up ELISA tests using S1 and nucleocapsid viral proteins confirmed most of these results. Our findings are consistent with seroprevalence studies within the region and with reports that SARS-COV-2 infections can be asymptomatic or cause only mild symptoms. IMPORTANCEThe COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has caused vast morbidity and mortality worldwide, yet several studies indicate that there may be a significant number of infected people who are asymptomatic or exhibit mild symptoms. In this study, samples were collected from healthy blood donors in a region of rapidly increasing disease burden (New York metropolitan area) and we hypothesized that a subset would be seropositive to SARS-CoV-2. People who experienced mild or no symptoms during SARS-CoV-2 infection may represent a source for convalescent plasma donors.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Long Term Accuracy of SARS-CoV-2 Interferon-γ Release Assay and its Application in Household Investigation 95%
- Clinical Validation of a Novel T-cell Receptor Sequencing Assay for Identification of Recent or Prior SARS-CoV-2 Infection 94%
- Measurement of SARS-CoV-2 antigens in plasma of pediatric patients with acute COVID-19 or MIS-C using an ultrasensitive and quantitative immunoassay 94%
Similar papers in this journal
- Nucleocapsid antigenemia is a marker of acute SARS-CoV-2 infection 94%
- Anti-SARS-CoV-2 Antibody Levels Associated with COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu VE Network, October 2021–June 2022 94%
- SARS-CoV-2 seroassay optimization and performance in a population with high background reactivity in Mali 93%
Similar papers in this journal
Similar papers in this journal
- Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of New York City Metro Blood Donors using Multiple SARS-CoV-2 Serological Assays: Implications for Controlling the Epidemic and Reopening. 95%
- Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform 94%
- Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2 92%
Similar papers in this journal
- Evaluation of commercially available high-throughput SARS-CoV-2 serological assays for serosurveillance and related applications 94%
- Detection of anti-nucleocapsid antibodies associated with primary SARS-CoV-2 infection in unvaccinated and vaccinated blood donors 93%
- Pre-pandemic SARS-CoV-2 serological reactivity in rural malaria-experienced Cambodians 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.